Well, the three shares in this article could be looking cheap after significant pullbacks.

Here's what you need to know about them:

Collins Foods Ltd (ASX: CKF)

The first ASX 200 share to look at is Collins Foods.

The KFC restaurant operator's shares are down approximately 20% this year, which has left it looking much cheaper than it did not long ago.

Collins Foods is not the kind of business that grabs attention like a high-growth technology stock. It operates in quick-service restaurants, where convenience, brand strength, and repeat customer behaviour are important.

Its core KFC operations give it exposure to one of the most recognised food brands in the world. That can be valuable during tougher economic periods, when consumers may still want affordable takeaway options but become more selective about bigger discretionary purchases.

Bell Potter is bullish on Collins Foods and has a buy rating and $10.80 price target on it.

Lovisa Holdings Ltd (ASX: LOV)

Another ASX 200 share that looks cheap after a selloff is Lovisa.

Its shares are down approximately 37% over the past 12 months, which is a sharp fall for a company that has delivered extraordinary growth over the long term.

Lovisa's story is not just about selling affordable jewellery. It is about a retail model that can be rolled out across many countries with relatively small-format stores, fast product rotation, and a brand that appeals to fashion-conscious shoppers.

That gives the company a very different growth profile from many local retailers. Its opportunity is global, and management has already shown it can open stores across multiple regions.

Morgans thinks the company has a bright future. It recently put a buy rating and $32.50 price target on its shares.

ResMed Inc. (ASX: RMD)

A third ASX 200 share to consider is ResMed.

The sleep treatment company's shares are down almost 30% over the past 12 months, which is a notable pullback for a global healthcare leader.

ResMed's products sit in an area of healthcare that is still underpenetrated. Sleep apnoea remains widely undiagnosed, despite its links to fatigue, cardiovascular risk, and broader health outcomes.

That gives the company a long-term demand driver that is not tied to the economic cycle in the same way as retail or housing. People may delay some purchases when money is tight, but healthcare needs do not disappear.

Ord Minnett is a big fan of the company. Last week, it put a buy rating and $38.35 price target on its shares

The post 3 cheap ASX 200 shares to buy with $5,000 appeared first on The Motley Fool Australia.

Experts have named all three as holds this week, according to The Bull, but why? Let's find out:

BHP shares

Morgans is a big fan of the Big Australian and believes it deserves its position as a core holding for resource-oriented portfolios.

However, due to recent share price strength, the broker thinks it is fairly valued and sees limited near term re-rating catalysts. As a result, it rates BHP shares as a hold. It explains:

The global miner offers broad diversification across iron ore, copper and potash, underpinned by a fortress balance sheet and a disciplined approach to capital returns. Copper provides meaningful long term exposure to the global electrification and energy transition theme, while iron ore remains the dominant near term earnings driver.

However, the macro backdrop remains uncertain, with Chinese steel demand facing structural headwinds and global growth indicators sending mixed signals. The valuation at current levels appears broadly fair, with commodity price assumptions already reflecting a reasonable medium term outlook. BHP remains a core holding for resource oriented portfolios, but with limited near term re-rating catalysts, we retain a hold recommendation.

Cochlear shares

Over at MPC Markets, its team has named Cochlear shares as a hold this week.

It highlights that the market has concerns over margins and procedure volumes. Until those concerns are resolved, MPC Markets thinks investors should sit on the sidelines. It said:

Cochlear remains a global leader in hearing implants, but the investment case has become more balanced. The shares have been under pressure after analysts re-assessed growth expectations and lowered revenue, margin and valuation assumptions. The long term demand profile remains attractive, supported by ageing populations and continued adoption of implantable hearing technology.

However, the market will need evidence that procedure volumes and margins can recover before a stronger recommendation is warranted. At these levels, investors can continue to hold, but should monitor earnings momentum and further analyst revisions.

ResMed shares

MPC Markets has also named ResMed as a hold this week.

Once again, this is partly due to concerns over margin uncertainty. Commenting on its hold recommendation, it said:

ResMed remains a high quality respiratory care business. Concerns about the impact of GLP-1 weight loss drugs have weighed on sentiment, although recent analysis suggests the big undiagnosed sleep apnoea market still provides a long runway for device demand.

The company continues to benefit from a strong mask and device portfolio, but investors were disappointed management left its fiscal year 2026 outlook unchanged after a solid third quarter result. Our hold recommendation balances the quality of the franchise against near term uncertainty around margins, competition and investor expectations.

The post Do experts rate BHP, Cochlear, and ResMed shares as buys, holds, or sells? appeared first on The Motley Fool Australia.

Let's check out 3 ASX 200 shares with new ratings from analysts on The Bull this week.

Resmed CDI (ASX: RMD)

The Resmed share price finished 1.3% higher at $28 yesterday.

Mark Gardner from MPC Markets has a hold rating on this ASX 200 healthcare share.

Gardner explained his view: 

ResMed remains a high quality respiratory care business. Concerns about the impact of GLP-1 weight loss drugs have weighed on sentiment, although recent analysis suggests the big undiagnosed sleep apnoea market still provides a long runway for device demand.

The company continues to benefit from a strong mask and device portfolio, but investors were disappointed management left its fiscal year 2026 outlook unchanged after a solid third quarter result.

Our hold recommendation balances the quality of the franchise against near term uncertainty around margins, competition and investor expectations.

Goodman Group (ASX: GMG)

The Goodman share price closed 0.32% higher at $31.20 on Tuesday.

Tony Locantro from Alto Capital has a sell rating on the ASX 200's biggest real estate share by market capitalisation.

Locantro says Goodman is seeking to capitalise on artificial intelligence (AI) while maintaining large exposure to logistics infrastructure. 

Data centres represent about 73% of the company's pipeline, and total work in progress is expected to reach about $18 billion this month.

Locantro discussed his sell rating on Goodman shares:

While the long term outlook for digital infrastructure remains highly attractive, investor enthusiasm surrounding AI and data centres has driven a substantial re-rating in the share price.

With significant growth expectations already reflected in the valuation, future returns may become increasingly dependent on flawless execution of large scale projects.

Given the strong share price performance and elevated market expectations, the risk-reward balance supports taking profits at current levels, in our view.

Westpac Banking Corp (ASX: WBC)

The Westpac share price finished 0.29% lower at $34.71 yesterday.

Damien Nguyen from Morgans has a sell rating on this ASX 200 bank share.

Nguyen said: 

Revenue growth appears constrained by a competitive mortgage market and subdued business lending conditions.

The bank has made meaningful progress on its strategic simplification agenda, shedding non-core businesses and improving its risk and compliance foundations.

The pathway to sustainable outperformance remains unclear. In our view, the recent share price doesn't offer a sufficient margin of safety in a challenging banking environment.

We see the risk–reward equation as unfavourable at recent levels.

The post Buy, hold, sell: Resmed, Goodman Group, Westpac shares appeared first on The Motley Fool Australia.

Shares in the S&P/ASX 200 Index (ASX: XJO) sleep disorder treatment company closed on Friday trading for $27.64. In afternoon trade on Tuesday, following the Monday King's Birthday ASX trading holiday, shares are swapping hands for $27.91 apiece, up 1%.

For some context, the ASX 200 is down 0.3% at this same time.

Taking a step back, however, ResMed shares remain down 28.2% over the past 12 months, materially lagging the 0.2% one-year gains of the benchmark index.

Which brings us back to our headline question.

Resmed shares: Buy, hold, or sell?

MPC Markets' Mark Gardner recently analysed the outlook for the ASX healthcare stock (courtesy of The Bull).

"ResMed remains a high-quality respiratory care business," he noted.

Addressing the past year's selling pressure, Gardner noted:

Concerns about the impact of GLP-1 weight loss drugs have weighed on sentiment, although recent analysis suggests the big undiagnosed sleep apnoea market still provides a long runway for device demand.

He added:

The company continues to benefit from a strong mask and device portfolio, but investors were disappointed management left its fiscal year 2026 outlook unchanged after a solid third quarter result.

Connecting the dots, Gardner issued a hold recommendation on ResMed shares.

"Our hold recommendation balances the quality of the franchise against near term uncertainty around margins, competition and investor expectations," he concluded.

What's the latest from the ASX 200 healthcare share?

ResMed released the third-quarter results Gardner mentioned above on 1 May.

Highlights included revenue of US$1.43 billion. That was up 11% year on year, or up 8% in constant currency.

The quarter also saw ResMed achieve an operating cash flow of US$554 million, with US$262 million returned to shareholders through share repurchases and dividends.

ResMed pays dividends on a quarterly basis.

"Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined execution of our strategy," ResMed CEO Mick Farrell said.

Farrell added:

These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of sleep health, breathing health, and healthcare in the home.

As we advance through the remainder of our fiscal year 2026, we remain focused on expanding access to care globally, scaling our digital health capabilities, and delivering further strong, profitable growth.

Amid high expectations and potentially the lack of an FY 2026 outlook upgrade, ResMed shares closed down 7.6% on the day of the results release.

The post Down 28% in a year, should I buy the dip on Resmed shares right now? appeared first on The Motley Fool Australia.

It is dealing with too many of them.

There are banks, miners, healthcare shares, retailers, technology companies, dividend shares, growth shares, and exchange-traded funds (ETFs). Every week brings new broker notes, market moves, and headlines.

So, how should an investor put money to work when they do not know what to buy?

This is how I would think about it.

Start with the job the investment needs to do

Before choosing a share, I would ask a simpler question: What do I want this investment to achieve?

If the goal is broad exposure, an ASX ETF could be the easiest answer. Something like the Vanguard Australian Shares Index ETF (ASX: VAS) can give investors exposure to a large group of Australian companies in one trade.

If the goal is global growth, an ETF such as the Vanguard MSCI Index International Shares ETF (ASX: VGS) could open the door to companies and sectors that are harder to access through the ASX alone.

If the goal is individual stock picking, I would then focus on business quality rather than trying to guess which share will move next week.

That first step matters because not every good investment does the same job.

Look for repeatable strengths

When I look at individual ASX shares, I want to understand why the business might be more valuable in five or 10 years.

That could come from a trusted brand, a powerful market position, recurring revenue, customer loyalty, scale, cost advantages, or a product that is difficult to replace.

For example, ResMed Inc (ASX: RMD) has a strong position in sleep health, with devices, masks, accessories, and software supporting ongoing treatment needs.

Macquarie Group Ltd (ASX: MQG) has a very different appeal. It is a global financial group with exposure to infrastructure, asset management, commodities, private capital, and market activity.

Neither business is perfect. But both have qualities that could allow them to keep building value over time.

That is the sort of thinking I would use. I would not ask only whether a share is popular today. I would ask whether the business has strengths that can keep showing up over many years.

Avoid needing one perfect pick

I do not think investors need to find the single best ASX share before getting started.

That can create too much pressure. Instead, I would think in layers. One investment might provide broad market exposure. Another might add global growth. Another might be a high-quality Australian business. Another might be a more ambitious growth idea.

This does not mean making things complicated. It just means accepting that different investments can play different roles, depending on what the investor is trying to achieve.

It also reduces the risk of putting too much weight on one decision.

Foolish Takeaway

Not knowing exactly what to buy is not a reason to stay on the side lines forever.

I think the better approach is to slow the decision down. Work out what the investment needs to do, focus on quality, and avoid making the whole plan depend on one perfect pick.

The share market will always feel uncertain. But investors do not need certainty to begin. They need a sensible process they can keep using, even when the headlines are noisy.

The post How to invest in ASX shares when you don't know what to buy appeared first on The Motley Fool Australia.

That is more than enough to start building exposure to some high-quality ASX 200 shares. The key is to focus on businesses with strong brands, durable earnings, and long-term growth opportunities.

With that in mind, here are three ASX 200 shares that could be worth a closer look.

Breville Group Ltd (ASX: BRG)

The first share to look at is Breville. It has become one of the ASX's more interesting global consumer businesses. It sells premium kitchen appliances across categories such as coffee, cooking, food preparation, and other home products.

What stands out is the company's ability to turn everyday appliances into higher-value products. A coffee machine is not just a coffee machine when customers are prepared to pay for better design, performance, and reliability.

That premium positioning has helped Breville build a brand that travels well beyond Australia. The United States is already a major market for the company, and there is still room to grow in other international regions.

Consumer spending can move through cycles, so investors should expect some bumps along the way. But Breville's product discipline, brand strength, and global runway make it a compelling growth option.

ResMed Inc (ASX: RMD)

Another ASX 200 share that could be worth considering is ResMed.

The company is a global leader in sleep apnoea treatment and respiratory care. Its devices, masks, accessories, and connected health platforms help patients manage chronic conditions and improve sleep quality.

This gives ResMed exposure to a large healthcare market with structural growth drivers. Sleep apnoea remains underdiagnosed in many countries, and awareness of the condition continues to increase.

The company also benefits from repeat demand. Once patients are using its devices, many continue to purchase masks, accessories, and support products over time.

That combination of medical need, global scale, and recurring product demand gives ResMed a strong long-term growth profile.

TechnologyOne Ltd (ASX: TNE)

A third ASX 200 share to consider for a $2,000 investment is TechnologyOne.

TechnologyOne provides enterprise software to organisations such as councils, universities, government departments, and large businesses. These customers use its systems to manage important functions across finance, payroll, assets, students, and administration.

Once software becomes embedded in these workflows, replacing it can be disruptive and costly. That gives TechnologyOne a sticky customer base and a strong recurring revenue foundation.

The company has also been expanding through its cloud-based model and growing internationally, particularly in the United Kingdom. This could provide another source of growth over the years ahead.

Overall, its consistency, defensive customer base, and scalable software model arguably make it one of the ASX's standout technology businesses.

The post Where to invest $2,000 in ASX 200 shares in June appeared first on The Motley Fool Australia.

I think that makes this a good time to look for ASX shares that could be best buys before FY27 begins.

The three shares in this article have strong long-term opportunities and I think they could be worth considering for investors.

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix Pharmaceuticals is one ASX share I would buy for FY27.

The company operates in radiopharmaceuticals, which is one of the more interesting areas of healthcare in my view. It is focused on products that can help detect and treat cancer more precisely.

That is the part of the story I find most compelling. Cancer care is moving towards better targeting, earlier detection, and more personalised treatment. Telix is exposed to that shift through imaging products, targeted therapies, and a growing pipeline.

This is not a simple healthcare stock. It carries clinical, regulatory, manufacturing, and commercial risks. The market can also change its view quickly when expectations around high-growth biotech companies move.

But I think Telix has already moved beyond being a purely speculative story. It has commercial products, global ambitions, and a pipeline that could become more valuable over time if management keeps executing.

FY27 could be another important year for the company as investors look for more evidence that Telix can turn its scientific position into durable earnings growth.

Catapult Sports Ltd (ASX: CAT)

Catapult Sports is another ASX share I think could be worth buying before FY27.

The company sells technology used by elite sporting teams to understand performance, training, tactics, workload, and recovery.

What interests me is how embedded this kind of technology can become inside a professional sports organisation. Clubs want information that helps coaches plan sessions, medical teams manage injury risk, analysts review performance, and players prepare more effectively.

That daily-use element is important.

I also think Catapult is becoming a more complete sports technology platform. Wearables remain part of the story, but the opportunity is broader across video, athlete monitoring, analysis, and workflow tools.

Elite sport is also global. Football, basketball, rugby, cricket, American football, and many other codes all want better information. The company does not need to win every team in every league to build a much larger business. It just needs to keep deepening its value with customers and expanding carefully.

ResMed Inc (ASX: RMD)

ResMed is the third ASX share I would buy for FY27.

The sleep health giant has been under pressure, but I think the long-term case remains attractive.

ResMed sells devices, masks, accessories, software, and connected care products for sleep apnoea and other respiratory conditions. But treatment does not necessarily end with a single sale. Patients often need replacement masks, ongoing support, monitoring, and long-term therapy management.

Sleep apnoea remains significantly underdiagnosed, but greater awareness of the condition has been encouraging more people to seek diagnosis over time. ResMed's leadership position, strong brand, scale, distribution, and product depth position it to win if that continues.

Foolish takeaway

The start of a new financial year can be a useful moment to reassess what kind of businesses are worth owning for the years ahead.

I am drawn to companies that are solving real problems in markets that still have room to grow. Cancer detection and treatment, elite sports performance, and sleep health all fit that description.

I think each of these ASX shares has enough long-term potential to be worth buying before the new financial year begins.

The post Which are the best ASX shares to buy now for FY27? appeared first on The Motley Fool Australia.

The S&P/ASX 200 Health Care Index (ASX: XHJ) is the worst performing sector by far in 2026 and has significantly unperformed the broader index. The decrease has pushed many major ASX healthcare companies to multi-year lows.

At the time of writing, the ASX 200 Health Care Index is down around 34% for the year to date and 47% lower than 12 months ago.

For context, the wider S&P/ASX 200 Index (ASX: XJO) is largely flat for the year to date and 3% higher than this time last year.

Sector wide declines might look concerning, but I think it presents a great opportunity for investors to buy into ASX 200 healthcare shares for cheap.

Here are three stocks that I'd buy today, while they're on sale.

ResMed Inc (ASX: RMD)

ResMed shares have fallen to a two-year low this week and are down 28% for the year so far. The global leader in sleep health was swept up in the general sector-wide ASX healthcare sell-off. Its latest third-quarter earnings update also came in softer than expected, which didn't help lessen declining sentiment. But I think the ASX 200 healthcare share is now oversold and below fair value. Sleep disorders require long-term management, and as a global leader, ResMed has a powerful position in a large (and growing) market. According to Market Index data, brokers have a strong buy consensus on ResMed shares and tip a 67% upside to an average $43.38 target price, at the time of writing.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

Fisher & Paykel shares have rebounded around 14% since hitting a two-year low in mid-May, but the shares have still got some more room to run before they return to 2025-levels. At the time of writing, the shares are still down around 6% for the year to date and they're 11% lower than 12 months ago. Investors have been buying this medical device company's shares following the release of its strong FY26 result last month, which showed investors that the business is sound. The ASX 200 healthcare company reported a 14% increase in total operating revenue and a 24% increase in NPAT. Brokers rate the shares as a strong buy and tip a potential 21% upside to an average $36.90 target price, at the time of writing.

Pro Medicus Ltd (ASX: PME)

Pro Medicus shares have rebounded around 21% since the health imaging technology company announced a new contract win. In late May, the ASX 200 healthcare company confirmed it has signed a five-year, A$28 million contract renewal with Allegheny Health Network (AHN). The increase has helped recoup some, but not all losses shed by the company over the past year. Pro Medics shares are still around 28% lower for the year to date and 43% below their trading price this time last year. The company's US subsidiary also won two $40 million five-year contract renewals back in early March. It looks like we'll see plenty more out of the company over the next 12 months, too. The majority of brokers rate the ASX 200 healthcare shares as a strong buy and tip an 18% upside to an average $188.51 target price, at the time of writing.

The post 3 ASX 200 healthcare shares to buy while they're on sale appeared first on The Motley Fool Australia.

When a share is making new lows, sentiment is often weak, investors are nervous, and the market is focused on what could still go wrong. That is not usually a comfortable time to buy.

But I think both healthcare leaders remain top buy and hold picks for patient investors.

The key is having the right time horizon. Buying at lows does not mean the share price will rebound quickly. But it does mean investors may be getting a better starting point in high-quality businesses that the market has stopped trusting for now.

CSL shares

CSL has had a difficult period. The market's confidence has been damaged by downgrades, margin pressure, weaker visibility, and concerns about parts of the plasma business. This is no longer the simple ASX healthcare compounder story that investors became used to over many years.

I think that is important to acknowledge. 

A recovery could take time. Investors may need to see better execution, clearer earnings momentum, and more confidence around margins before sentiment turns in a meaningful way.

But I do not think CSL's long-term investment case has disappeared.

The company still has global leadership positions across plasma therapies, vaccines, and specialist medicines. Its products are tied to real healthcare needs, not short-term consumer trends. Demand for immunoglobulins and other critical therapies should remain supported over time, even if the business is working through operational and commercial challenges today.

This is why I think buying near 52-week lows could be attractive. The market is no longer pricing CSL as though everything is easy. Expectations have been reset, and that can create a better setup for investors willing to wait.

ResMed shares

ResMed has also been sold down heavily, but I think the business remains very strong.

The company is a global leader in sleep health, with a business model that combines devices, masks, accessories, software, and connected care.

I like that mix because the need is ongoing. Patients do not simply buy a device and disappear. Treatment often involves replacement masks, support, data, monitoring, and long-term therapy management.

The sleep apnoea market also remains underpenetrated. Many people are still undiagnosed, and awareness of the condition can keep improving over time.

There has been plenty of debate about risks, including drug competition and newer treatment approaches. But I still think ResMed has a powerful position in a large global market.

GLP-1 weight loss drugs, in particular, may not be the negative that investors first feared. They may not be for everyone and could also encourage more people to engage with their health, seek diagnosis, and understand the impact of sleep apnoea.

That does not mean the share price will recover overnight. But for long-term investors, I think the current weakness could be a chance to buy a world-class healthcare business at a more attractive price.

Foolish takeaway

Buying shares at 52-week lows can feel uncomfortable because the market is usually telling a negative story.

But that can be where the opportunity begins.

I do not think CSL or ResMed will suddenly regain investor confidence overnight. Both need patience, and both could remain volatile while the market waits for clearer evidence.

Even so, I think these are the kinds of businesses worth studying when sentiment is poor. They have strong market positions, global healthcare exposure, and long-term demand drivers that should still matter years from now.

The post Are CSL and ResMed shares buys at 52-week lows? appeared first on The Motley Fool Australia.

As the calendars turn over to June, the S&P/ASX 200 Health Care Index (ASX: XHJ) sits almost 33% lower than at the start of the year. 

This makes it the worst performing sector in 2026 by some margin. 

ASX healthcare shares have been hit by a combination of earnings downgrades, rising cost pressures, weaker overseas earnings and investor concerns that growth across the sector is slowing. 

Because healthcare makes up a large part of the Australian market's growth-stock universe, higher interest rates and a strong rotation into energy, mining, and resource stocks have amplified the sell-off.

For investors, this could be an intriguing opportunity to gain exposure to quality companies at a historic discount. 

Here are three of the largest ASX healthcare stocks that are tipped to rebound from historic lows. 

Pro Medicus Ltd (ASX: PME)

Pro Medicus enjoyed a fast start to the month of June. 

The medical imaging technology company rose over 9% yesterday following a key contract win.

Investors will be hoping this is the start of a long-term rebound. 

Despite yesterday's 9% gain, it remains down 35% year to date. 

It closed yesterday at $144.46 per share. 

However brokers are confident it will rise significantly higher in the next 12 months. 

13 analysts offering a one year forecast have an average price target of $187.27 on Pro Medicus shares, indicating roughly 3% upside from current levels. 

11 of the 13 analysts rate the stock as a strong buy or buy. 

ResMed Inc (ASX: RMD)

While Pro Medicus shares started June off with a big rise, it was the opposite start to the month for ResMed shares. 

ResMed is a global leader in sleep technology.

Its share price fell more than 7% yesterday, and is now down 26% year to date. 

It now sits at a new 52-week low of $26.27. 

However this could now be a rare opportunity to scoop up this ASX healthcare stock at a significant value. 

Morgans expects a rebound over the next 12 months. The broker has a price target of $41.72 along with a buy rating. 

This indicates an upside potential of almost 59%. 

Sonic Healthcare Ltd (ASX: SHL)

It has been a similarly difficult 2026 for Sonic Healthcare shares. 

Its share price is down more than 14% year to date. 

However the global healthcare provider could also be set to recover in the near term. 

12 analysts forecasts via TradingView have an average one year price target of $23.40 on this ASX healthcare stock. 

This indicates an upside potential of 21% from current levels. 

The post Is June set to be the month of the ASX healthcare rebound? appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

DroneShield Ltd (ASX: DRO)

The DroneShield share price is down 10.5% to $3.03. This is despite there being no news out of the counter-drone technology company on Monday. However, it is worth noting that there is optimism that the US and Iran will soon sign a peace deal. This could mean that investors are fearing that demand for DroneShield's products will soften.

Lendlease Group (ASX: LLC)

The Lendlease share price is down over 3% to $2.63. Investors have been selling the property developer's shares following the announcement of a divestment. The company has agreed a $250 million sale agreement for its MSG North development rights. However, this deal is expected to result in a $175 million post‑tax loss. Management notes that the transaction is part of Lendlease's ongoing capital recycling program, which is intended to release value tied up in long-dated and complex projects. Lendlease's CEO, Tony Lombardo, said: "The sale of the commercially challenged MSG North project is consistent with our strategy to reduce long-dated international development capital and simplify the Group."

Playside Studios Ltd (ASX: PLY)

The Playside Studios share price is down 30% to 16.5 cents. This has been driven by news that tech giant Meta Platforms (NASDAQ: META) is terminating its agreement for outsourced development contracts on the Horizon Worlds social platform. Management anticipates the revenue impact from the loss of this work will be approximately A$4 million in FY 2027. It said: "This is a counterparty decision and is not a reflection of the work PlaySide employees have delivered on an engagement that has consistently grown in value and scope since initial work began with Facebook in 2021. However, the loss of this work is a setback to the Company's External Projects pipeline, and rebuilding that pipeline is (and has been) the immediate priority. Over the past six months we have built out the Company's Business Development function from one person to four, significantly expanding the Company's reach with international clients, and that team is focused on the work ahead."

ResMed Inc (ASX: RMD)

The ResMed share price is down 7% to $26.63. This follows a sharp decline by the sleep treatment company's NYSE-listed shares on Friday night. There does not appear to have been any obvious company-specific catalyst for the weakness on Wall Street.

The post Why DroneShield, Lendlease, PlaySide, and ResMed shares are tumbling today appeared first on The Motley Fool Australia.

Diversification is important, but there is also a point where a portfolio can become so crowded that the best ideas barely move the needle.

If I were aiming for $1 million in retirement using ASX 200 shares, I would keep the plan simple. I would try to own around 10 high-quality businesses, invest regularly, reinvest dividends, and give compounding as much time as possible.

Where to start

Let's say an investor starts with $10,000 and adds $500 a month.

If that portfolio returned an average of 9% per annum, it could grow to more than $1 million in around 30 years.

That return is not guaranteed. Share markets do not move in a straight line, and some years can be painful. But I think the example shows why time, consistency, and reinvestment are so powerful.

The investor does not need to find the next tiny stock that rises 20-fold. They need a sensible plan and the discipline to keep going through different market conditions.

Why just 10 ASX 200 shares?

I would not want my retirement plan to depend on one or two companies. That is too much single-stock risk.

But I also do not think I need to own every company on the ASX.

Owning 10 carefully selected ASX 200 shares could give exposure to different sectors, earnings drivers, and growth opportunities without making the portfolio too diluted.

For example, a portfolio could include Commonwealth Bank of Australia (ASX: CBA) for banking quality and fully franked dividends, Macquarie Group Ltd (ASX: MQG) for global financial exposure, BHP Group Ltd (ASX: BHP) for resources and copper, and Wesfarmers Ltd (ASX: WES) for retail and industrial strength.

I would also want healthcare exposure through ResMed Inc (ASX: RMD) and CSL Ltd (ASX: CSL), digital infrastructure through Goodman Group (ASX: GMG), property platform exposure through REA Group Ltd (ASX: REA), enterprise software through TechnologyOne Ltd (ASX: TNE), and global technology through WiseTech Global Ltd (ASX: WTC).

That is not a perfect list for every investor. But it shows the sort of balance I would want.

What I'd look for

The share price is only one part of the decision.

If I were building a retirement portfolio, I would care more about the quality of the business than whether the stock looks cheap on the day I buy it.

I would want companies with strong competitive positions, capable management, durable demand, and the ability to keep reinvesting for growth.

Dividends would also matter. Over decades, reinvested dividends can make a huge difference. Fully franked income from some ASX 200 shares can also be useful, depending on an investor's tax situation.

But I would not build the whole portfolio around yield. A retirement portfolio still needs growth.

Staying the course

The hardest part of this plan would not be choosing the 10 shares. It would be holding them through market falls.

Over 30 years, there will almost certainly be recessions, interest rate scares, earnings disappointments, commodity sell-offs, and company-specific problems.

That is normal. I would review the portfolio regularly, but I would not want to trade it constantly. The aim would be to own strong businesses for long enough that their earnings, dividends, and reinvestment have time to compound.

Foolish takeaway

A $1 million retirement portfolio can sound like a distant target, but it becomes more realistic when the plan is broken down.

I would start with quality, keep the portfolio focused, add money consistently, and let time do its work.

Ten ASX 200 shares will not remove every risk. But if they are chosen carefully and held patiently, I think they could form the backbone of a portfolio capable of building serious retirement wealth.

The post I'd aim for $1 million in retirement buying just 10 ASX 200 shares appeared first on The Motley Fool Australia.

I am less interested in what a company might do next quarter and more interested in whether it can still be relevant, useful, and growing many years from now.

That does not mean ignoring valuation or risk. But it does mean looking for businesses with long runways and strong positions in markets that should keep expanding.

Three ASX 200 shares I would consider buying for the next 20 years are named in this article.

ResMed Inc (ASX: RMD)

ResMed is one ASX 200 share I think could still be a high-quality business two decades from now.

The company is a global sleep health leader, with devices, masks, accessories, and software used to treat sleep apnoea and other breathing-related conditions.

What I like is the ongoing nature of the need. Sleep apnoea is not a short-term trend. Many people remain undiagnosed, and awareness of the condition can still grow. As healthcare systems put more focus on prevention, chronic disease, heart health, and quality of life, sleep health could become even more important.

ResMed also has a useful business model. Devices are important, but masks, accessories, connected care, and software can keep customers engaged over time.

Competition and pricing pressure remain risks, but I think ResMed has the brand, scale, and market position to keep growing for many years.

Goodman Group (ASX: GMG)

Goodman Group is another ASX 200 share I would consider for a long holding period.

The business has already evolved from a traditional industrial property company into a global owner, developer, and manager of scarce logistics and data centre sites.

I like Goodman because it is exposed to two major long-term shifts. The first is the need for efficient logistics space close to major cities and transport routes. The second is the growing demand for data centre infrastructure, driven by cloud computing, digital services, and artificial intelligence.

Goodman's advantage is not just owning property. It has development skill, customer relationships, capital partners, and access to locations that can be difficult to replicate.

The share price can be sensitive to interest rates and expectations around data centres. But over 20 years, I think high-quality infrastructure in the right places could become even more valuable.

Sigma Healthcare Ltd (ASX: SIG)

Sigma Healthcare has become a very attractive long-term idea since merging with Chemist Warehouse.

The combined business gives investors exposure to pharmacy retail, healthcare distribution, wellness products, and repeat-purchase health needs.

I like this because healthcare retail can have a different demand profile from many discretionary categories. Consumers may pull back on plenty of things, but medicines, health products, prescriptions, and pharmacy services remain important.

Chemist Warehouse also gives Sigma a powerful brand, scale, and a large customer base.

The opportunity over the next 20 years is not just about selling more products. It is about using scale, distribution, data, store networks, and brand strength to build a larger healthcare retail platform.

Another positive is the recent expansion into the UK market. This could be a key driver of growth over the next two decades if it executes successfully.

Foolish takeaway

When I think about investing for 20 years, I want businesses that can keep finding new ways to grow.

That does not mean every year will be smooth. It means the long-term need behind the business remains strong.

Sleep health, digital infrastructure, logistics, pharmacy, and everyday healthcare are not areas I expect to disappear. That is why I think these three ASX 200 shares could be worth buying with a genuinely long-term mindset.

The post I'd buy these ASX 200 shares if I wanted to invest for the next 20 years appeared first on The Motley Fool Australia.

CSL Ltd (ASX: CSL), Cochlear Ltd (ASX: COH), and ResMed Inc (ASX: RMD) have all tumbled to multi-year lows this year as a toxic combination of earnings downgrades, sector rotation, and macro headwinds drove investors toward energy and resources stocks.

But dramatic selloffs in high-quality businesses have a habit of creating opportunities for investors who can think past the next quarter.

Here is where each stock stands today.

CSL

The fall at CSL has been extraordinary by any measure.

CSL shares are down approximately 43% in 2026 and more than 60% over the past twelve months, hitting a 10-year low in recent weeks.

The most recent catalyst was another guidance downgrade.

Interim CEO Gordon Naylor lowered FY2026 revenue expectations to approximately US$15.2 billion on a constant currency basis following a 90-day strategic review.

The market's patience has run out.

Management has cited weakness in China albumin pricing, inventory normalisation in the US immunoglobulin market, and operational challenges as the primary drivers.

The bull case rests on CSL's plasma-derived therapies business, which operates behind barriers to entry that no competitor has been able to meaningfully breach in decades.

Plasma collection volumes have recovered from post-COVID lows.

What's more, the Vifor integration is progressing.

And insiders are now buying shares on market for the first time in years, a signal that those closest to the business believe the selloff has gone too far.

The market wants proof of such a sustained recovery, and that means a sustained recovery in sentiment may still take several quarters to materialise.

But at current prices, CSL trades on a valuation it has not seen since before the pandemic.

Cochlear

Cochlear's 2026 has been even more brutal than CSL's.

The shares are down 62% year to date, touching an eleven-year low in recent weeks.

The April guidance downgrade, which cut FY2026 underlying net profit from $435 to $460 million down to $290 to $330 million, was one of the worst earnings cuts in the company's listed history.

The causes were a mix of the temporary and the concerning.

Hospital capacity constraints, reduced referral activity, and Middle East disruptions pushed patients to delay surgery.

Cost of living pressures in the US appear to be causing some patients to treat cochlear implants as discretionary rather than essential, at least in the short term.

However, the long-term demand picture has not changed.

Cochlear holds approximately 50% global market share in cochlear implants, with just 3% penetration of an addressable market exceeding six million people in developed markets alone.

Brokers including Jarden and Wilsons Advisory still see significant upside from current levels, with some flagging upside of more than 100% over twelve months.

CEO Dig Howitt said:

The clinical need for cochlear implants continues to grow, particularly for the adult and seniors segment… cochlear implants are also associated with a lower incidence of dementia.

Investors should note that surgeries are being delayed, not cancelled.

ResMed

ResMed's 2026 selloff is being driven by fears about GLP-1 obesity drugs threatening demand for CPAP devices.

Those fears have proven to be significantly overstated.

The company's own data from 1.7 million patients shows that patients on both GLP-1 therapy and CPAP therapy actually show higher adherence rates than those on CPAP alone.

In Q3 FY2026, ResMed delivered revenue of US$1.29 billion, up 11% year-on-year, with operating income rising 22% and gross margins improving to 58.9%.

CEO Mick Farrell said at the earnings call:

We believe GLP-1s are truly a megatrend, and a once-in-a-generation demand-gen opportunity for ResMed Inc.

Yet the shares remain down approximately 22% in 2026 as sentiment lags the fundamental reality.

At current prices, ResMed trades materially below fair value according to analysts who have updated their models following the Q3 result.

Foolish takeaway

CSL, Cochlear, and ResMed are three of the highest-quality healthcare businesses ever listed on the ASX.

All three are dealing with headwinds that are temporary, cyclical, or based on fears that have not materialised.

That does not mean the bottom is in, and near-term volatility will likely continue.

But for investors with multi-year time horizons, the entry points available in each of these ASX healthcare stocks today look considerably more attractive than anything on offer in the past five years.

The post These 3 ASX healthcare stocks have been crushed in 2026. They could be set for a comeback appeared first on The Motley Fool Australia.

The world is ageing, medical technology keeps improving, and patients are demanding better diagnosis, treatment, and care. That does not mean every healthcare share will do well, but I think the sector could produce some excellent long-term winners.

Three ASX 200 healthcare shares I would buy for the future are named in this article.

ResMed Inc (ASX: RMD)

ResMed is one of the ASX 200 healthcare shares I rate most highly.

The company is a global leader in sleep health, with products that help treat sleep apnoea and other respiratory conditions. I like the business model because it combines devices with recurring revenue from masks, accessories, and software.

That recurring element is important. A patient does not just buy a device once and disappear forever. They often need replacement masks, ongoing support, connected data, and better tools to manage therapy.

I also think the long-term market remains underpenetrated. Many people with sleep apnoea remain undiagnosed, and awareness of the condition can still improve.

There has been plenty of debate about GLP-1 weight loss drugs and what they mean for sleep apnoea treatment. I see them as more of an awareness driver than a simple threat. If more patients engage with their health, seek diagnosis, and understand the risks of untreated sleep apnoea, ResMed could still benefit.

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix is a higher-risk healthcare growth share, but I think the opportunity is compelling.

The company is focused on radiopharmaceuticals, including cancer imaging and targeted treatment. This is a specialised area of healthcare with the potential to improve how certain cancers are detected and treated.

What I like about Telix is that it is not simply a clinical-stage dream. It already has a commercial base, while still investing in a pipeline that could create future growth.

That combination is attractive, but it also comes with risk. Clinical trials can disappoint, regulatory timelines can change, and healthcare investors can quickly lose patience when expectations are high.

I would not put Telix in the same risk bucket as a mature healthcare leader like ResMed. But for investors comfortable with more volatility, I think Telix offers exposure to one of the more interesting areas of modern cancer care.

If management can keep growing the commercial business and advance the pipeline, the company could look very different in a decade.

Cochlear Ltd (ASX: COH)

Cochlear has had a difficult period, but I still think it deserves attention from long-term investors.

The company is a global leader in implantable hearing solutions. Its products can make a major difference to people with severe to profound hearing loss, and I think the long-term need is clear.

Ageing populations should support demand over time. Diagnosis and treatment access can also improve, especially as hearing loss becomes more widely understood as a serious health issue rather than simply an inconvenience.

Cochlear's near-term outlook has been challenged, and confidence has weakened. But I do not think the long-term healthcare need has gone away.

For patient investors, the question is whether the current pressure is temporary or structural. I lean towards the former, although recovery may take time.

Foolish Takeaway

Healthcare investing often requires patience.

A company can have a strong long-term market and still go through periods where sentiment turns against it. That is why I like looking for businesses with real clinical need behind them, not just a fashionable story.

These three ASX 200 shares carry different risks, but they all have something I want in a healthcare investment: a reason to exist that should still matter many years from now.

The post 3 ASX 200 shares I'd buy for the future of healthcare appeared first on The Motley Fool Australia.

For ResMed Inc (ASX: RMD), the debate has centred on a single question: If millions of people lose weight and no longer suffer from sleep apnea, what happens to demand for CPAP machines?

It is a fair question, and for most of 2025, the market answered it by selling ResMed shares aggressively, at one point sending them to a multi-year low as investors priced in an existential threat to the company's core business.

Today, the evidence suggests that fear was significantly overstated, and that GLP-1 drugs may actually be one of the most powerful demand drivers ResMed has encountered in years.

Why the fear made sense initially

The bear case was not irrational.

Between 70% and 90% of obstructive sleep apnea cases are driven by obesity, meaning a drug that reliably reduces body weight could logically reduce the addressable market for CPAP devices over time.

That concern became more acute when Eli Lilly's GLP-1 drug Zepbound received FDA approval to treat obstructive sleep apnea directly, without requiring a CPAP machine.

This marked the first time a pharmaceutical had been approved as an alternative to device therapy for the condition.

ResMed shares fell sharply on that news, and the stock spent much of 2025 in what analysts described as the penalty box, maintained on watch lists but held back from buy recommendations pending clarity on whether GLP-1 adoption would materially erode device demand.

But the real-world data tells a different story

The most important piece of evidence came from ResMed's own Q3 FY 2026 earnings call, where CEO Mick Farrell presented new data drawn from a cohort of 1.7 million de-identified patients.

The finding was striking.

PAP patients who subsequently start GLP-1 therapy show higher PAP adherence rates than patients on PAP alone, with two-year resupply rates 5.1% higher and three-year resupply rates 6.2% higher.

In other words, patients who take GLP-1 drugs while using CPAP therapy are more likely to keep using their devices, not less. Farrell went further, stating directly on the call:

We believe GLP-1s are truly a megatrend, and a once-in-a-generation demand-gen opportunity for ResMed Inc. Both GLP-1s and wearables alike are driving more patients to talk with their doctors and ultimately, we believe this will lead to more patients coming into the ResMed Inc. ecosystem.

Why GLP-1s are actually driving more patients to ResMed

As GLP-1 drugs become mainstream and patients visit doctors more frequently to manage their weight, they are also being screened for obesity-related conditions they may not have known they had, including sleep apnea.

According to ResMed, approximately one billion people worldwide are affected by sleep apnea, the vast majority of whom remain undiagnosed.

GLP-1 adoption is bringing millions of those undiagnosed patients into the healthcare system for the first time, and a meaningful proportion of them are receiving sleep apnea diagnoses and CPAP prescriptions as a result.

Furthermore, a meta-analysis published in GeroScience showed that individuals with sleep apnea have a 33% higher risk of developing dementia, and that sleep apnea was associated with a 45% increased risk of Alzheimer's disease.

That evidence is motivating payers, health systems, and physicians to screen and treat sleep apnea more aggressively than ever before.

The financial performance backs it up

ResMed's most recent quarterly results leave little doubt about the health of the underlying business.

In Q3 FY 2026, the company delivered revenue of US$1.29 billion, up 11% year on year, with operating income rising 22% and gross margins improving to 58.9%.

The software and services segment, which manages patient data and remote monitoring across more than 23 billion nights of sleep data, grew at a double-digit rate and now generates more than US$200 million per quarter.

ResMed shares remain down in 2026, a hangover from the GLP-1 fear trade that has not yet fully unwound.

Foolish Takeaway

ResMed was sold down on a fear that turned out to be wrong, or at least far less threatening than investors assumed.

The company's own data now shows that GLP-1 adoption is increasing CPAP adherence, bringing more undiagnosed patients into the healthcare system, and creating what management has described as a once-in-a-generation demand opportunity.

For investors who can look past a year of negative sentiment and focus on what the numbers actually say, ResMed looks like one of the more interesting large-cap healthcare opportunities on the ASX today.

The post The global obesity drug boom could be bigger than investors realise for this ASX stock appeared first on The Motley Fool Australia.

That is why I think quality should sit at the centre of the portfolio.

Three ASX shares I think could suit that role are named in this article.

ResMed Inc (ASX: RMD)

ResMed is an ASX healthcare share I would be happy to own in an SMSF.

The company is a global leader in sleep apnoea treatment and connected respiratory care. Its devices help patients start therapy, while masks, accessories, software, and data tools support ongoing treatment.

I like that model for a long-term portfolio. The initial device sale is only part of the story. Patients often need replacement masks, cushions, tubing, and other supplies. That creates a recurring element that can support high margins and long-term earnings growth.

The sleep health market also remains underpenetrated. Many people with sleep apnoea have not been diagnosed or treated, which gives ResMed a long runway if awareness and testing continue to improve.

There are risks from competition and new treatment options, but I think ResMed's brand, scale, and patient ecosystem remain valuable.

Xero Ltd (ASX: XRO)

Xero is another world-class business I would consider for an SMSF.

This ASX share provides cloud accounting and financial software for small businesses, accountants, and bookkeepers.

What I like is that Xero can become part of the operation of a small business. Invoicing, payroll, payments, tax, reporting, and cash flow are not occasional tasks. They are central to how a business runs.

That gives the platform a strong position if it continues improving.

Xero also has a large international opportunity. Australia and New Zealand are strong markets, but the UK and US could provide a much longer runway if management executes well.

Artificial intelligence (AI) could add another growth engine. Small business owners often spend too much time on admin. If Xero can automate more of that work, its software could become even more valuable.

For an SMSF, I think Xero offers exposure to a global software business with many years of growth still ahead.

Macquarie Group Ltd (ASX: MQG)

Macquarie Group would give an SMSF a very different type of world-class exposure.

It is not a traditional Australian bank. Macquarie has operations across asset management, commodities and global markets, banking, financial services, and investment banking.

That variety is one reason I like it. The group can benefit from infrastructure investment, energy transition, commodities volatility, private markets, capital flows, and specialist financing.

Earnings can be uneven from year to year. That is part of owning a business exposed to markets and investment activity.

But over long periods, Macquarie has shown an impressive ability to adapt and find attractive areas to deploy capital.

I think that adaptability is valuable for an SMSF with a long horizon.

Foolish Takeaway

An SMSF portfolio does not need to be filled with only defensive assets. I think there is room for high-quality growth shares that can compound over many years.

ResMed, Xero, and Macquarie share one useful trait: they have built strong positions that would be difficult for competitors to copy quickly.

That is the kind of business I would want working inside a super portfolio for the long term.

The post I would buy these world-class ASX shares for an SMSF appeared first on The Motley Fool Australia.

There are thousands of companies, daily market moves, broker opinions, dividend forecasts, interest rate headlines, and economic data points.

But I think the best starting point is much simpler.

A beginner does not need to know everything on day one. The goal is to build a sensible process, buy quality assets, and let time do some of the heavy lifting.

Start with the purpose

The first question I would ask is: What am I investing for?

Some investors want long-term growth. Others want passive income. Some want a mix of both.

That answer can shape the types of ASX shares that make sense.

For long-term growth, I would focus on companies with strong market positions and room to expand. For income, I would look for businesses with reliable earnings and dividends that appear sustainable.

A beginner could also use exchange-traded funds (ETFs) to get started, but individual ASX shares can play an important role if chosen carefully.

Keep the first few choices simple

When starting out, I think it is worth looking at businesses that are easy to understand.

Wesfarmers Ltd (ASX: WES) is one example. The group owns brands that reach across everyday Australian spending, including Bunnings, Kmart, Officeworks, and Priceline. It also has exposure to industrial earnings and lithium through Mt Holland.

That mix gives investors exposure to several parts of the economy in one company.

Telstra Group Ltd (ASX: TLS) is another ASX share I think beginners could understand quickly. Mobile and internet services are part of daily life, giving the company a defensive advantage. The dividend can also appeal to investors wanting income.

For healthcare exposure, ResMed Inc (ASX: RMD) could be worth considering. It is a global sleep health business with devices, masks, accessories, and software. I like that it has a recurring revenue element because patients often need replacement products over time.

Do not try to be perfect

One of the biggest mistakes beginners can make is waiting for the perfect entry point. The market rarely makes things obvious.

If prices fall, investors worry they will fall further. If prices rise, investors worry they have missed the opportunity.

That is why I recommend investing gradually. A beginner might invest a set amount each month or quarter. This reduces the pressure of trying to time the market and helps build the habit of investing.

Focus on quality and patience

The ASX will always have speculative shares promising huge upside.

Some will succeed, but many (or most) will disappoint.

For a beginner, I think quality should come first. That means strong brands, useful products, recurring revenue, healthy balance sheets, and management teams with a record of execution.

The returns may not be exciting every month. But over many years, owning better businesses can make a huge difference.

Foolish Takeaway

Starting in 2026 requires a first step and a plan that is easy to keep following.

I think beginners can do well by starting with understandable businesses, investing gradually, and giving compounding time to work.

There will be corrections, bad headlines, and moments when cash feels safer. That is part of the journey.

But the investors who keep buying quality through those periods give themselves a real chance of building wealth over time.

The post How to start investing in ASX shares in 2026 appeared first on The Motley Fool Australia.

I think that is a useful mindset for ASX investors right now. There are plenty of risks in the market, from higher interest rates and weaker consumer spending to geopolitical uncertainty and questions around company earnings.

But there are also a number of high-quality ASX shares trading well below where they were not long ago.

That is why I think this could be a good time to be greedy, selectively.

Quality healthcare at lower prices

One area I would be looking at closely is healthcare.

CSL Ltd (ASX: CSL) has had a brutal year, and investor confidence has been badly damaged. The company has disappointed the market, and it needs to prove that earnings growth can become more reliable again.

But I still think CSL owns valuable healthcare assets across plasma therapies, vaccines, and specialist medicines. These are global businesses linked to real medical demand, not short-term consumer trends.

At today's much lower share price, I think investors may be getting a rare chance to buy CSL while expectations are very low.

I also think ResMed Inc. (ASX: RMD) looks interesting after its own selloff.

ResMed is a global leader in sleep apnoea treatment, with devices, masks, accessories, and software that support patients and healthcare providers. I like its high-margin, recurring revenue characteristics. Once a patient is in therapy, there can be ongoing demand for masks, cushions, and other supplies.

There are concerns around possible drug competition in sleep apnoea, but I think the market may be underestimating the durability of ResMed's position.

Fallen growth shares

I would also be looking at selected ASX growth shares.

WiseTech Global Ltd (ASX: WTC) has fallen heavily from its highs, but I still think the long-term opportunity is compelling.

Global trade is complicated. Freight forwarders and logistics companies deal with customs, compliance, documentation, routing, warehousing, and cross-border regulation. WiseTech's software sits inside those workflows.

That is exactly the kind of position I like in a technology business. If the software becomes deeply embedded, it can be difficult for customers to replace.

The stock still carries risks around valuation, acquisitions, execution, and investor sentiment. But after such a large fall, I think the market may be offering long-term investors a better entry point.

Consumer shares with recovery potential

Some consumer-facing ASX shares also look interesting after major declines.

Harvey Norman Holdings Ltd (ASX: HVN) is exposed to a difficult retail environment, with households under pressure and big-ticket spending under strain. But I think the business still has valuable retail brands, property assets, and a history of rewarding shareholders with dividends.

Accent Group Ltd (ASX: AX1) is another beaten-up name that could appeal to patient investors. Footwear and apparel spending can be cyclical, but Accent owns a broad portfolio of banners and brands across sport, lifestyle, and youth fashion.

If consumer confidence improves over time, I think the recovery potential could be meaningful.

Finally, Amcor plc (ASX: AMC) could offer a different kind of cheap ASX share. Packaging may not be exciting, but it is used across food, beverages, healthcare, and consumer goods. I like the defensive nature of that demand, especially when the share price is out of favour.

Foolish takeaway

Being greedy does not mean buying every ASX share that has fallen. Some selloffs are deserved, and some businesses will not recover the way investors hope.

But I think Buffett's broader lesson still applies. Fear can create better prices for investors who are willing to think beyond the next few months.

CSL, ResMed, WiseTech, Harvey Norman, Accent, and Amcor are all facing different challenges. That is why they are cheaper today.

For me, the opportunity is in separating temporary disappointment from permanent damage. When good businesses are priced as though the future is much darker than it may prove to be, I think patient investors should be ready to act.

The post I'd listen to Warren Buffett and load up on cheap ASX shares appeared first on The Motley Fool Australia.

By the time confidence returns, some of the best opportunities may already have moved. That is why it can be worth looking for quality ASX shares while sentiment is still mixed.

The aim is not to chase the hottest stock of the week. It is to find businesses with strong long-term drivers that could benefit when investors become more willing to back growth again.

Here are three ASX shares I'd be looking at before the next market rally.

Breville Group Ltd (ASX: BRG)

Breville is an ASX share I'd be happy to buy before confidence improves.

The company has built a global premium appliance business with coffee at the centre of its growth story. Its espresso machines have benefited from the shift toward better coffee at home, particularly among consumers willing to pay for quality.

That category gives Breville more than a one-off product sale. Coffee sits in daily routines, and the company has built credibility with consumers who care about performance, design, and consistency.

Breville also has room to grow internationally through its Breville, Sage, Baratza, and Lelit brands. Expansion in the United States, Europe, and newer markets gives the business several levers beyond Australia.

If consumer sentiment improves and premium spending stabilises, Breville could be well placed to keep building on its global growth story.

Megaport Ltd (ASX: MP1)

Megaport is a smaller and more volatile idea, but its market opportunity is significant.

This ASX share helps businesses connect to cloud providers, data centres, and networks through its on-demand connectivity platform. As companies continue shifting workloads into the cloud, the need for flexible digital infrastructure keeps growing.

Megaport's recent acquisition of Latitude.sh expands the company beyond connectivity and into compute infrastructure, increasing its addressable market.

That is important because cloud and artificial intelligence demand are not only software stories. They require networks, compute capacity, and infrastructure that can scale quickly.

Megaport still has to execute well. But if it can turn its broader platform into stronger revenue and earnings growth, the share price could have significant upside over the long term.

ResMed Inc (ASX: RMD)

ResMed Inc remains one of the highest-quality healthcare businesses on the ASX.

The company develops devices, masks, and software used to treat sleep apnoea and other breathing-related conditions. These are not discretionary products. They sit in an area of healthcare where diagnosis, treatment, and ongoing patient management is important.

What makes ResMed interesting is the size of the untreated market. Management estimates that there are over 1 billion sufferers of sleep apnoea globally, with the vast majority still undiagnosed. This means demand can continue growing as awareness improves and more patients enter treatment.

The company also benefits from connected devices and digital tools that help patients and healthcare providers manage therapy over time. That gives ResMed a stronger position than a simple medical device manufacturer.

If investors rotate back toward reliable global growth businesses, ResMed could be one of the ASX shares that attracts attention.

The post I'd buy these 3 ASX shares before the next market rally appeared first on The Motley Fool Australia.